Erythrocyte Complement Receptor 1 and Alzheimer Disease

Alzheimer Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01565434
• Other study ID #: PA11014
• Status: Completed
• Phase: N/A
• First received: March 26, 2012
• Last updated: June 8, 2016
• Start date: February 2012
• Est. completion date: April 2015

Study information

• Verified date: March 2012
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

• diseases modifying CR1 physiology

Study Design

Primary Purpose: Screening

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Other:
• CR1 impact

Locations

Country	Name	City	State
France	CHU de REIMS	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France,